Literature DB >> 3081573

Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators.

P B Bitterman, M D Wewers, S I Rennard, S Adelberg, R G Crystal.   

Abstract

Tissue fibrosis results, in part, from an interaction between growth regulatory molecules released by mononuclear phagocytes and fibroblasts. In the chronic interstitial lung disorders, alveolar macrophages, the mononuclear phagocytes of the lung, are known to spontaneously release two growth factors for fibroblasts, fibronectin and alveolar macrophage-derived growth factor (AMDGF) that together stimulate nonreplicating lung fibroblasts to divide. In addition to these two primary growth promoting signals, alveolar macrophages are able to release other mediators that may have a potential role in modulating lung fibroblast replication in response to these primary signals, including interferon gamma (IFN gamma), prostaglandin E2 (PGE2), and interleukin 1 (IL-1). To evaluate this possibility, we examined the effect of each of these other mediators on lung fibroblast replication in response to fibronectin and AMDGF in serum-free, defined medium. IFN gamma had no effect on fibroblast replication. In contrast, PGE2 resulted in a dose-dependent inhibition of fibroblast replication in response to fibronectin and AMDGF with 50% of the maximum inhibition observed at a PGE2 concentration of less than 10 ng/ml. IL-1, while not active as a primary growth promoting signal, at concentrations of 4-10 U/ml, augmented fibroblast replication in response to fibronectin and AMDGF by 10 to 15%. Temporally, the growth augmenting effect of IL-1 occurred early in the G1 phase of the cell cycle. These data indicate that lung fibroblast replication in response to two of the primary growth promoting signals spontaneously released by alveolar macrophages in the interstitial lung disorders, while uninfluenced by IFN gamma, can be inhibited by PGE2 and modestly augmented by IL-1. Understanding the relevant fibroblast growth modulatory signals within the alveolar microenvironment in the chronic interstitial disorders may lead to rational therapeutic strategies designed to interrupt the fibrotic process.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081573      PMCID: PMC423453          DOI: 10.1172/JCI112364

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Interleukin 1, a potential regulator of fibroblast proliferation.

Authors:  J A Schmidt; S B Mizel; D Cohen; I Green
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

2.  Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation.

Authors:  L J Rosenwasser; C A Dinarello
Journal:  Cell Immunol       Date:  1981-09-01       Impact factor: 4.868

3.  Enzyme-linked immunoassay (ELISA) for connective tissue components.

Authors:  S I Rennard; R Berg; G R Martin; J M Foidart; P G Robey
Journal:  Anal Biochem       Date:  1980-05-01       Impact factor: 3.365

4.  Differences in domain structures between plasma and cellular fibronectins.

Authors:  M Hayashi; K M Yamada
Journal:  J Biol Chem       Date:  1981-11-10       Impact factor: 5.157

5.  Role of attachment factors and attractants in fibroblast chemotaxis.

Authors:  V Gauss-Müller; H K Kleinman; G R Martin; E Schiffmann
Journal:  J Lab Clin Med       Date:  1980-12

6.  Fibronectin in human bronchopulmonary lavage fluid. Elevation in patients with interstitial lung disease.

Authors:  S I Rennard; R G Crystal
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

7.  Modulation of collagen production following bleomycin-induced pulmonary fibrosis in hamsters. Presence of a factor in lung that increases fibroblast prostaglandin E2 and cAMP and suppresses fibroblast proliferation and collagen production.

Authors:  J G Clark; K M Kostal; B A Marino
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

8.  Human monocyte-derived growth factor(s) for mesenchymal cells: activation of secretion by endotoxin and concanavalin A.

Authors:  K C Glenn; R Ross
Journal:  Cell       Date:  1981-09       Impact factor: 41.582

9.  Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases.

Authors:  S I Rennard; G W Hunninghake; P B Bitterman; R G Crystal
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

10.  Pulmonary injury in rats following continuous exposure to 60% O2 for 7 days.

Authors:  G Hayatdavoudi; J J O'Neil; B E Barry; B A Freeman; J D Crapo
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-11
View more
  66 in total

1.  Heparin/endothelial cell growth supplement regulates matrix gene expression and prolongs life span of vascular smooth muscle cells through modulation of interleukin-1.

Authors:  J Y Hsu; M Y Hsu; T Sorger; M Herlyn; E M Levine
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

2.  Continuous secretion of monocyte chemotactic factors and fibroblast growth factors by alveolar macrophages following a single exposure to bleomycin in vitro.

Authors:  E M Denholm
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

3.  Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts.

Authors:  Masanori Nakanishi; Tadashi Sato; Yingji Li; Amy J Nelson; Maha Farid; Joel Michalski; Nobuhiro Kanaji; Xingqi Wang; Hesham Basma; Amol Patil; Jadvinder Goraya; Xiangde Liu; Shinsaku Togo; Myron L Toews; Olaf Holz; Kai-Christian Muller; Helgo Magnussen; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02       Impact factor: 6.914

4.  Innovative therapies in the treatment of keloids and hypertrophic scars.

Authors:  Martha H Viera; Sadegh Amini; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-05

Review 5.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

6.  SARS-CoV regulates immune function-related gene expression in human monocytic cells.

Authors:  Wanchung Hu; Yu-Ting Yen; Sher Singh; Chuan-Liang Kao; Betty A Wu-Hsieh
Journal:  Viral Immunol       Date:  2012-08       Impact factor: 2.257

7.  Heterogeneity in hormone responses and patterns of collagen synthesis in cloned dermal fibroblasts.

Authors:  S R Goldring; M L Stephenson; E Downie; S M Krane; J H Korn
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

8.  Anti-scarring effects of butaprost on human subconjunctival Tenon's fibroblasts.

Authors:  Jong Hoon Shin; Je Hyun Seo; Jae Ho Jung; Tae Woo Kim
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

9.  Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2.

Authors:  J Wilborn; L J Crofford; M D Burdick; S L Kunkel; R M Strieter; M Peters-Golden
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.